Microneedle Eye Patch FAQ

We support private-label and custom OEM or ODM project planning. The available formula, geometry, packaging, sample and production scope is confirmed after technical and commercial review.

Private label starts from an existing platform, OEM adapts a defined brand specification, and ODM adds deeper formula or engineering development. Ownership, evidence responsibilities and change control should be agreed in writing.

Match the contracting company, physical site, process scope and certificates; then review a traceable batch record and hold a live production walkthrough. A company may outsource a step, but it should disclose who performs it and who releases the batch.

Provide destination market, cosmetic claim direction, formula or benchmark, patch and array requirements, pair count, pouch and carton scope, first-order quantity, annual forecast, sample need and desired launch window.

There is no responsible universal MOQ. It depends on formula, tooling, primary and secondary packaging minimums, testing, line setup and production efficiency. Ask which component or process creates the quoted minimum.

Timing depends on novelty, sample rounds, materials, tooling, testing, packaging and approvals. A schedule becomes reliable only when inputs, decision owners, specifications and commercial terms are agreed.

Yes, subject to cosmetic eligibility, compatibility, processing, analytical capability, eye-area safety and target-market requirements. A qualified starting platform normally carries fewer technical unknowns than a new formula.

Potential concepts include hyaluronic acid, caffeine, acetyl tetrapeptide-5, acetyl hexapeptide-8, copper tripeptide-1 and defined multi-peptide systems. Every material must be reviewed in the actual matrix and market.

There is no universal best peptide. Choose from the cosmetic objective, exact raw-material identity, matrix compatibility, processing exposure, stability, evidence and permitted claim—not search popularity or ingredient count.

Patch contour, array footprint, projection height, base width, pitch, density, backing and pouch can be evaluated together. Custom tooling changes feasibility, cost, minimum quantity and timing.

A dissolvable microdart or microneedle patch has a dry micro-array formed from a soluble matrix. A hydrogel eye patch is a hydrated gel sheet without the same projection architecture; manufacturing, packaging and claims should not be treated as equivalent.

Wear and dissolution time are finished-product specifications, not universal category numbers. Matrix composition, residual moisture, geometry, application pressure, skin condition, backing and instructions all affect observed behavior.

Yes, where feasible. Define whether the sample is for formula feasibility, fit, array integrity, packaging, pilot confirmation or consumer feedback; an early laboratory sample does not establish shelf life or production repeatability.

Record formula and geometry revision, package, storage history, appearance, dimensions, missing or deformed projections, liner removal, handling, fit and agreed use observations. Mark each criterion as descriptive or pass/fail.

Request site- and scope-relevant quality certificates, raw-material specifications, draft finished-product specification, certificate-of-analysis fields, batch traceability, release tests, stability plan, packaging specification and change-notification terms.

Relevant parameters can include array formation, morphology, dimensions, structural integrity, active distribution where applicable, drying or residual-moisture control, microbiological quality, pouch seal and stability in the commercial pack.

Potential formats include single-pair barrier pouches, cartons and multi-pair kits. Unused patches should remain protected, and the final pack must support handling, storage, directions, traceability and destination-market labeling.

Re-evaluate changes to active supplier or grade, polymer, formula ratio, process hold time, drying, mold or geometry, backing, pouch structure, seal settings, production site, claims, directions or target market.

Safety cannot be established from the category name alone. The finished formula, array, microbiological controls, package, stability, directions, use area and target population require product-specific assessment before commercialization.

No blanket global guarantee is appropriate. Classification, ingredient eligibility, safety file, claims, label, responsible-party and notification or registration duties must be confirmed for each finished product and market.

Use appearance- and care-oriented claims supported by the finished product, such as hydration or temporary smoothing where substantiated. Avoid disease treatment, drug delivery, permanent structural change, injection-equivalence or unsupported clinical promises.

The manufacturer supplies accurate product and process information; the brand owner or designated responsible party should complete qualified market-specific classification, safety, claims, notification and label review before sale.

The evidence plan should reflect formula, geometry, instructions, exposure, target population and destination market. It may include ingredient review, finished-product safety assessment, microbiological quality, stability, package compatibility and claim substantiation.

No. These names relate to prescription or investigational drug programs, not cosmetic peptide ingredients. We do not offer them as cosmetic patches, private-label skincare products or weight-loss patches.